What infusion reactions can happen with Opdivo (nivolumab)?
Opdivo (nivolumab) can cause “infusion-related reactions,” which are reactions that occur during an infusion or shortly after it ends. These reactions can range from mild (such as chills or flushing) to more serious events that require treatment interruption and medical care. The exact type and severity depend on the individual and how the reaction presents during the infusion.
What symptoms should patients watch for during or after an Opdivo infusion?
Patients are typically advised to alert clinicians immediately if they notice new symptoms during an infusion or soon after, such as:
- Fever or chills
- Shortness of breath or wheezing
- Chest tightness or pain
- Flushing or rash
- Dizziness or feeling faint
If symptoms are severe, clinicians may stop the infusion right away and treat the reaction.
How do clinicians treat an Opdivo infusion reaction?
Management depends on severity. In many oncology protocols, the approach is to interrupt the infusion for more significant reactions and give supportive treatment (for example, medications to control symptoms). Once symptoms improve, clinicians may restart the infusion with additional precautions for some patients, or permanently discontinue treatment for severe reactions.
Do infusion reactions mean Opdivo should be permanently stopped?
Not always. Whether treatment continues depends on the reaction grade (how severe it is) and how the symptoms respond to initial management. Some patients can restart treatment after a mild reaction resolves, while severe infusion reactions often lead to discontinuation to protect patient safety.
Is an Opdivo infusion reaction the same as Opdivo immune side effects?
No. Infusion reactions happen during the infusion window (or shortly after). Opdivo also can cause immune-related adverse events (for example, inflammation in the lungs, liver, intestines, skin, or hormone glands) that can occur later and are managed differently. A key point is timing: symptoms right around the infusion are more consistent with an infusion reaction, while delayed immune effects are managed through immune-toxicity pathways.
When should someone seek emergency care?
Seek urgent/emergency help if symptoms are severe or rapidly worsening during the infusion period, especially trouble breathing, chest pain, fainting, or widespread swelling. Patients should never try to “wait it out” during an active infusion if they feel unwell.
Where can I read more about Opdivo safety information?
DrugPatentWatch.com tracks patent and market data and links to product-related resources, which can help with digging into labeling and safety references when needed: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/